Table 1.
Baseline characteristics between patients with NACE and non-NACE
| Characteristic | Total (n = 2159) |
non-NACE (n = 2120) |
NACE (n = 39) |
P value |
|---|---|---|---|---|
| Age (year) | 64.23 ± 10.25 | 64.12 ± 10.26 | 70.15 ± 7.75 | < 0.001 |
| Age ≥ 65 years | 1086 (50.3%) | 1058 (49.9%) | 28 (71.8%) | 0.007 |
| Weight (kg) | 66.49 ± 12.14 | 66.55 ± 11.93 | 63.25 ± 20.55 | 0.323 |
| Male sex | 1591 (73.7%) | 1569 (74.0%) | 22 (56.4%) | 0.013 |
| Smoking | 601 (27.8%) | 590 (27.8%) | 11 (28.2%) | 0.959 |
| CHF | 274 (12.7%) | 264 (12.5%) | 10 (25.6%) | 0.014 |
| CKD | 382 (17.7%) | 370 (17.5%) | 12 (30.8%) | 0.031 |
| MI history | 342 (15.8%) | 334 (15.8%) | 8 (20.5%) | 0.420 |
| Prior PCI | 400 (18.5%) | 397 (18.7%) | 3 (7.7%) | 0.079 |
| Prior CABG | 22 (1.0%) | 22 (1.0%) | 0 (0.0%) | 0.523 |
| Stroke | 160 (7.4%) | 158 (7.5%) | 2 (5.1%) | 0.583 |
| Atrial fibrillation | 71 (3.3%) | 70 (3.3%) | 1 (2.6%) | 0.798 |
| Hypertension | 1490 (69.0%) | 1463 (69.0%) | 27 (69.2%) | 0.976 |
| Diabetes mellitus | 715 (33.1%) | 698 (32.9%) | 17 (43.6%) | 0.301 |
| Hyperlipemia | 473 (21.9%) | 462 (21.8%) | 11 (28.2%) | 0.337 |
| Clopigrel or Ticagrelor | 2139 (99.1%) | 2100 (99.1%) | 39 (100.0%) | 0.553 |
| Clopigrel/Ticagrelor loading | 1422 (65.9%) | 1398 (65.9%) | 24 (61.5%) | 0.565 |
| Aspirin | 2105 (97.6%) | 2067 (97.6%) | 38 (97.4%) | 0.934 |
| Aspirin loading | 554 (25.7%) | 534 (25.2%) | 20 (51.3%) | < 0.001 |
| Cilostazol | 52 (2.4%) | 50 (2.4%) | 1 (2.6%) | 0.007 |
| Statin | 2123 (98.5%) | 2085 (98.4%) | 38 (100.0%) | 0.438 |
| DAPT | 2092 (97.0%) | 2054 (97.0%) | 38 (97.4%) | 0.881 |
| Warfarin | 13 (0.6%) | 13 (0.6%) | 0 (0.0%) | 0.624 |
| ACEI/ARB | 1650 (76.5%) | 1622 (76.5%) | 28 (71.8%) | 0.488 |
| CCB | 544 (25.2%) | 527 (24.9%) | 17 (43.6%) | 0.008 |
| Nitric acid merged | 1294 (60.0%) | 1262 (59.6%) | 32 (82.1%) | 0.004 |
| Beta blockers | 1804 (83.6%) | 1770 (83.5%) | 34 (87.2%) | 0.542 |
| Tirofiban | 204 (9.4%) | 192 (9.1%) | 12 (30.8%) | < 0.001 |
| Number of stents | 2 (1 ~ 3) | 2 (1 ~ 3) | 2 (1 ~ 3) | 0.047 |
| Total length of stents (mm) | 39 (24 ~ 66) | 38 (24 ~ 65) | 51 (33 ~ 84) | 0.023 |
| Diagnosis | 0.472 | |||
| Unstable angina | 1227 (56.9%) | 1207 (57.0%) | 20 (51.3%) | |
| NSTEMI | 928 (43.1%) | 909 (43.0%) | 19 (48.7%) | |
| Cys-c (mg/L) | 1.20 ± 1.77 | 1.19 ± 1.78 | 1.44 ± 0.98 | 0.138 |
| Creatinine (μmol/l) | 94.14 ± 69.35 | 93.47 ± 66.16 | 130.28 ± 166.34 | 0.176 |
| Estimated GFR (ml/min/1.73 m2) | ||||
| c-aGFR | 86.98 ± 29.53 | 87.19 ± 29.45 | 75.18 ± 32.21 | 0.012 |
| CG | 73.03 ± 27.93 | 73.31 ± 27.88 | 57.71 ± 26.58 | 0.001 |
| CKD-EPIcr | 77.18 ± 21.52 | 77.40 ± 21.41 | 65.37 ± 24.65 | 0.001 |
| CKD-EPICys-C | 71.72 ± 26.44 | 71.91 ± 26.36 | 61.23 ± 29.33 | 0.012 |
| CKD-EPIcr-Cys-C | 65.70 ± 21.18 | 65.90 ± 21.10 | 55.16 ± 23.13 | 0.002 |
CHF chronic heart failure, CKD chronic kidney disease, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, DAPT dual antiplatelet therapy, ACEI/ARB aldosterone receptor inhibitors and aldosterone receptor antagonist, CCB calcium channel blocker, NSTEMI non-ST segment elevation myocardial infarction, eGFR estimated glomerular filtration rate